Development of the Ganglioside GD2 as a Biomarker and Clinical Trial Endpoint for Childhood Cancers

Email Principal Investigator
Asset 5.png

Frank M. Balis

Children’s Hospital of Philadelphia
Philadelphia, PA, USA

CBTN Specimen


CBTN Participants


CBTN Samples




About this


GD2 is a molecule expressed on the surface of tumors such as high grade glioma or medulloblastoma. and GD2 has many of the characteristics of an ideal biomarker. Biomarkers can be used as therapeutic targets for the treatment of cancer and can also serve to provide accurate prognostics and predict treatment response. The goal of this project is to determine GD2 concentrations in patients with a variety of common childhood cancers, including brain tumors, and in children without cancer. Researchers hypothesize that GD2 will not be quantifiable in the serum of patients with most common types of childhood cancer and children without cancer and that GD2 is a tumor-specific biomarker for neuroblastoma and brain tumors. The Children's Brain Tumor Network contributed to this project by providing plasma samples that will be screened for the presence of GD2. Validation of GD2 as a tumor biomarker opens the door to new therapies and could help to expedite clinical trial processes leading to faster development.

Ask The


Ask the scientists

What are the goals of this project?

Researchers seek to validate GD2 as a tumor biomarker through the analysis of plasma samples.

What is the impact of this project?

If validated, GD2 based therapies verified by this project could lead to the acceleration of clinical trial processes, thus bringing novel therapies to patients as quickly as possible.

Why is the CBTN request important to this project?

The Children’s Brain Tumor Network will support this project through the provision of serum samples from across pediatric brain tumor types.



Specimen Data

The Children's Brain Tumor Network contributed to this project by providing plasma samples.